Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV

AIM: To assess selected cardiorenal outcomes with ertugliflozin according to use of baseline glucose‐lowering agent. MATERIALS AND METHODS: VERTIS CV was a cardiovascular (CV) outcome trial for ertugliflozin versus placebo, conducted in patients with type 2 diabetes and established atherosclerotic C...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagogo‐Jack, Samuel, Cannon, Christopher P., Cherney, David Z. I., Cosentino, Francesco, Liu, Jie, Pong, Annpey, Gantz, Ira, Frederich, Robert, Mancuso, James P., Pratley, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314942/
https://www.ncbi.nlm.nih.gov/pubmed/35266296
http://dx.doi.org/10.1111/dom.14691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314942/
https://www.ncbi.nlm.nih.gov/pubmed/35266296
http://dx.doi.org/10.1111/dom.14691

Ejemplares similares